• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

ALYREF通过调控EZH2促进乳腺癌进展。

ALYREF enhances breast cancer progression by regulating EZH2.

作者信息

Jeong Su-Jin, Oh Ji Hoon, Cho Je-Yoel

机构信息

Department of Biochemistry, College of Veterinary Medicine, Research Institute for Veterinary Science, and BK21 PLUS Program for Creative Veterinary Science Research and Research Institute for Veterinary Science, Seoul National University, Seoul, 08826, Republic of Korea.

Comparative Medicine Disease Research Center, Seoul National University, Seoul, 08826, Republic of Korea.

出版信息

Heliyon. 2024 Sep 16;10(19):e37749. doi: 10.1016/j.heliyon.2024.e37749. eCollection 2024 Oct 15.

DOI:10.1016/j.heliyon.2024.e37749
PMID:39386827
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11462240/
Abstract

Breast cancer is one of the most common malignant tumors in women worldwide. Similarly, Canine mammary tumors (CMTs) are mostly diagnosed as spontaneous diseases in female dogs. Many studies have suggested that CMTs serve as good models for human breast cancer. However, comparative approaches to histone modifications are still lacking. This study aimed to compare the canine mammary tumor Histone H3 lysine 4 trimethylation (H3K4me3) landscape with that in human breast cancer. Our H3K4me3 ChIP-seq data from CMTs revealed a significant enrichment of H3K4me3 in the ALYREF gene promoter in tumor tissues compared to normal tissues. Furthermore, our study and publicly available RNA-sequencing data revealed that expression was elevated in malignant tissues and breast cancer cell lines, and its upregulation was associated with poor prognosis in humans. Depletion of ALYREF resulted in changes in cellular phenotypes, including increased proliferation and colony formation, as well as decreased apoptosis increased cell viability and anchorage-independent growth while decreasing apoptosis by regulating the mRNA expression and protein levels of enhancer of zeste 2 polycomb repressive complex 2 subunit (EZH2), which promotes hormone receptor-positive breast cancer and CMTs via epigenetic modifications. This suggests that may function as a contributing factor to malignant transformation in both CMT and human breast cancer.

摘要

乳腺癌是全球女性中最常见的恶性肿瘤之一。同样,犬乳腺肿瘤(CMTs)大多被诊断为雌性犬的自发性疾病。许多研究表明,CMTs可作为人类乳腺癌的良好模型。然而,目前仍缺乏对组蛋白修饰的比较研究方法。本研究旨在比较犬乳腺肿瘤中组蛋白H3赖氨酸4三甲基化(H3K4me3)图谱与人类乳腺癌中的图谱。我们来自CMTs的H3K4me3 ChIP-seq数据显示,与正常组织相比,肿瘤组织中ALYREF基因启动子区域的H3K4me3显著富集。此外,我们的研究以及公开可用的RNA测序数据表明,其在恶性组织和乳腺癌细胞系中的表达升高,并且其上调与人类的不良预后相关。敲低ALYREF会导致细胞表型发生变化,包括增殖增加、集落形成增加以及凋亡减少,同时通过调节增强子zeste 2多梳抑制复合物2亚基(EZH2)的mRNA表达和蛋白水平来增加细胞活力和非锚定依赖性生长,而EZH2通过表观遗传修饰促进激素受体阳性乳腺癌和CMTs。这表明ALYREF可能是CMT和人类乳腺癌恶性转化的一个促成因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d86/11462240/435590f9dd95/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d86/11462240/62b375c89d2c/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d86/11462240/3d12fea3c769/gr3a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d86/11462240/13323854c21a/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d86/11462240/435590f9dd95/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d86/11462240/62b375c89d2c/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d86/11462240/3d12fea3c769/gr3a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d86/11462240/13323854c21a/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d86/11462240/435590f9dd95/gr6.jpg

相似文献

1
ALYREF enhances breast cancer progression by regulating EZH2.ALYREF通过调控EZH2促进乳腺癌进展。
Heliyon. 2024 Sep 16;10(19):e37749. doi: 10.1016/j.heliyon.2024.e37749. eCollection 2024 Oct 15.
2
Expression of a constitutively active prolactin receptor causes histone trimethylation of the p53 gene in breast cancer.组成型活性催乳素受体的表达导致乳腺癌中p53基因的组蛋白三甲基化。
Chin Med J (Engl). 2014;127(6):1077-83.
3
Significance of EZH2 expression in canine mammary tumors.EZH2表达在犬乳腺肿瘤中的意义
BMC Vet Res. 2016 Aug 9;12(1):164. doi: 10.1186/s12917-016-0789-2.
4
The histone methyltransferase EZH2 promotes mammary stem and luminal progenitor cell expansion, metastasis and inhibits estrogen receptor-positive cellular differentiation in a model of basal breast cancer.在基底样乳腺癌模型中,组蛋白甲基转移酶EZH2可促进乳腺干细胞和管腔祖细胞的扩增、转移,并抑制雌激素受体阳性细胞的分化。
Oncol Rep. 2015 Jul;34(1):455-60. doi: 10.3892/or.2015.4003. Epub 2015 May 21.
5
In utero exposure to diethylstilbestrol (DES) or bisphenol-A (BPA) increases EZH2 expression in the mammary gland: an epigenetic mechanism linking endocrine disruptors to breast cancer.子宫内暴露于己烯雌酚(DES)或双酚-A(BPA)会增加乳腺中的 EZH2 表达:一种将内分泌干扰物与乳腺癌联系起来的表观遗传机制。
Horm Cancer. 2010 Jun;1(3):146-55. doi: 10.1007/s12672-010-0015-9.
6
EZH2 and histone deacetylase inhibitors induce apoptosis in triple negative breast cancer cells by differentially increasing H3 Lys acetylation in the gene promoter and enhancers.EZH2和组蛋白去乙酰化酶抑制剂通过差异性增加基因启动子和增强子中H3赖氨酸乙酰化来诱导三阴性乳腺癌细胞凋亡。
Oncol Lett. 2017 Nov;14(5):5735-5742. doi: 10.3892/ol.2017.6912. Epub 2017 Sep 8.
7
Regulation of the expression of claudin 23 by the enhancer of zeste 2 polycomb group protein in colorectal cancer.结直肠癌中zeste 2多梳蛋白家族增强子对claudin 23表达的调控
Mol Med Rep. 2015 Jul;12(1):728-36. doi: 10.3892/mmr.2015.3378. Epub 2015 Feb 19.
8
Enhancer of zeste homolog 2 (EZH2) promotes progression of cholangiocarcinoma cells by regulating cell cycle and apoptosis.增强子结合锌指蛋白 2(EZH2)通过调节细胞周期和细胞凋亡促进胆管癌细胞的进展。
Ann Surg Oncol. 2013 Dec;20 Suppl 3:S667-75. doi: 10.1245/s10434-013-3135-y. Epub 2013 Jul 26.
9
Epigenetic regulation of cell adhesion and communication by enhancer of zeste homolog 2 in human endothelial cells.EZH2 通过增强子结合锌指蛋白 2 对人内皮细胞黏附和通讯的表观遗传调控。
Hypertension. 2012 Nov;60(5):1176-83. doi: 10.1161/HYPERTENSIONAHA.112.191098. Epub 2012 Sep 10.
10
Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells.表观遗传疗法用 3-去氮杂胞苷 A,一种组蛋白甲基转移酶 EZH2 的抑制剂,抑制非小细胞肺癌细胞的生长。
Lung Cancer. 2012 Nov;78(2):138-43. doi: 10.1016/j.lungcan.2012.08.003. Epub 2012 Aug 25.

本文引用的文献

1
Integrative mapping of the dog epigenome: Reference annotation for comparative intertissue and cross-species studies.整合犬类表观基因组图谱:用于比较组织间和跨物种研究的参考注释。
Sci Adv. 2023 Jul 7;9(27):eade3399. doi: 10.1126/sciadv.ade3399. Epub 2023 Jul 5.
2
TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer.TONSL 是乳腺癌中的永生化癌基因和治疗靶点。
Cancer Res. 2023 Apr 14;83(8):1345-1360. doi: 10.1158/0008-5472.CAN-22-3667.
3
ALYREF mediates RNA mC modification to promote hepatocellular carcinoma progression.
ALYREF介导RNA mC修饰以促进肝细胞癌进展。
Signal Transduct Target Ther. 2023 Mar 18;8(1):130. doi: 10.1038/s41392-023-01395-7.
4
COMMD proteins function and their regulating roles in tumors.COMMD蛋白的功能及其在肿瘤中的调控作用。
Front Oncol. 2023 Jan 23;13:1067234. doi: 10.3389/fonc.2023.1067234. eCollection 2023.
5
ABCA9, an ER cholesterol transporter, inhibits breast cancer cell proliferation via SREBP-2 signaling.ABCA9,内质网胆固醇转运蛋白,通过 SREBP-2 信号抑制乳腺癌细胞增殖。
Cancer Sci. 2023 Apr;114(4):1451-1463. doi: 10.1111/cas.15710. Epub 2023 Jan 18.
6
ALYREF, a novel factor involved in breast carcinogenesis, acts through transcriptional and post-transcriptional mechanisms selectively regulating the short NEAT1 isoform.ALYREF,一种新的参与乳腺癌发生的因子,通过选择性调节短的 NEAT1 异构体的转录和转录后机制起作用。
Cell Mol Life Sci. 2022 Jul 1;79(7):391. doi: 10.1007/s00018-022-04402-2.
7
The multiple mechanisms of MCL1 in the regulation of cell fate.MCL1 在调控细胞命运中的多重机制。
Commun Biol. 2021 Sep 2;4(1):1029. doi: 10.1038/s42003-021-02564-6.
8
Over-expression of SRD5A3 and its prognostic significance in breast cancer.SRD5A3 的过表达与乳腺癌的预后意义。
World J Surg Oncol. 2021 Aug 31;19(1):260. doi: 10.1186/s12957-021-02377-1.
9
METTL8 mRNA Methyltransferase Enhances Cancer Cell Migration via Direct Binding to ARID1A.METTL8 mRNA 甲基转移酶通过直接结合 ARID1A 增强癌细胞迁移。
Int J Mol Sci. 2021 May 21;22(11):5432. doi: 10.3390/ijms22115432.
10
CCDC137 Is a Prognostic Biomarker and Correlates With Immunosuppressive Tumor Microenvironment Based on Pan-Cancer Analysis.基于泛癌分析,CCDC137是一种预后生物标志物且与免疫抑制性肿瘤微环境相关。
Front Mol Biosci. 2021 May 13;8:674863. doi: 10.3389/fmolb.2021.674863. eCollection 2021.